AngioDynamics received FDA 510(k) clearance and began international clinical trials in Europe and Hong Kong.
1 report, 0 independent
Updated Jun 23
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AngioDynamics received FDA 510(k) clearance and began international clinical trials in Europe and Hong Kong.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
AngioDynamics (United States)
company in California City, United States
Nothing else this week.
- FDA
Related events
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- FDA granted 510(k) clearance to Masimo for its AFib monitoring capability.
- FDA granted 510(k) clearance for a new panel developed by Hoffmann-La Roche.
Coverage
Newest first; wire copies grouped- Unknown outlet